(Q38217108)

31 August 2017

title

Vaccine responsiveness in the elderly: best practice for the clinic (English)

1 reference

31 August 2017

1 reference

Richard Aspinall

1

1 reference

31 August 2017

Pierre Olivier Lang

series ordinal

2

1 reference

31 August 2017

publication date

3 June 2014

1 reference

Expert Review of Vaccines

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

885-894

1 reference

Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

The Avalanche is Coming … And Just Now It's Starting to Snow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Travel-associated illness in older adults (>60 y).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Influenza vaccine: a travelers' vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Global trends in emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

The outbreak of West Nile virus infection in the New York City area in 1999

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

The next decade of vaccines: societal and scientific challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Designing tomorrow's vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Promoting life course vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

The principles and feasibility of disease eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Immune senescence and vaccination in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Dysregulation of human Toll-like receptor function in aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Thymic atrophy in the mouse is a soluble problem of the thymic environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

B cell immunosenescence: different features of naive and memory B cells in elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Ageing is associated with a decline in peripheral blood CD56bright NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Aging, frailty and age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Complications of viral influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

The annual production cycle for influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Determinants of immunity to influenza infection in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Immunogenicity and protective efficacy of influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Influenza control in the 21st century: Optimizing protection of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Association of influenza vaccination and reduced risk of recurrent myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Immune senescence and vaccines to prevent herpes zoster in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Assessment of vaccine candidates for persons aged 50 and older: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Vaccination against Herpes Zoster and Postherpetic Neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Contagious diseases in the United States from 1888 to the present.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Rationale for pertussis booster vaccination throughout life in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

How long do nosocomial pathogens persist on inanimate surfaces? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Travel vaccines and elderly persons: review of vaccines available in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Tracing thymic output in older individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Variability in the immune system: of vaccine responses and immune states

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

An Immune Risk Phenotype, Cognitive Impairment, and Survival in Very Late Life: Impact of Allostatic Load in Swedish Octogenarian and Nonagenarian Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.924403

10.1586/14760584.2014.924403

21 January 2018

Identifiers

DOI

1 reference

release_42l77nf4ivdlxe3pyztrluqvee

31 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/42l77nf4ivdlxe3pyztrluqvee

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference